Erasca Reports Strong Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015 in Solid Tumors
ERAS has more than doubled off its 52-week low of $1.06 on elevated volume (4.1× avg).
Summary
Erasca, Inc. announced positive preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing robust objective response rates and favorable safety in RAS-mutant solid tumors, exceeding comparator data.
Key Events · Product Development and Regulatory · ERAS
-
Positive Phase 1 Data for ERAS-0015
Preliminary results show robust monotherapy objective response rates (ORR) in KRAS G12X NSCLC (up to 75% uORR) and PDAC (up to 42% uORR), exceeding comparator data.
-
Significant Tumor DNA Reduction
100% of patients (14/14) at pharmacologically active doses showed at least 75% reduction in KRAS G12X circulating tumor DNA, with 5 patients achieving 100% reduction.
-
Favorable Safety Profile
ERAS-0015 was generally well-tolerated with mostly low-grade adverse events, no dose-limiting toxicities, and no discontinuations due to treatment-related adverse events.
-
Advancement of Pipeline
Monotherapy expansion and combination dose escalation cohorts initiated ahead of schedule, with further data expected in H1 2027 for ERAS-0015 and H2 2026 for ERAS-4001.
Analysis · ERAS · Life Sciences
This 8-K provides the highly anticipated Phase 1 data for ERAS-0015, a pan-RAS molecular glue, following the company's announcement on April 21, 2026, that it would narrow the readout timeline. The results are significantly positive, demonstrating robust objective response rates (ORR) in difficult-to-treat KRAS G12X NSCLC and PDAC, with reported efficacy exceeding a comparator drug. The observed substantial reductions in circulating tumor DNA and a favorable safety profile further de-risk the asset and validate Erasca's therapeutic approach. This strong clinical validation for a key pipeline candidate is a major catalyst for the company, despite the separate, negative news of a patent infringement allegation disclosed earlier today. Investors will likely focus on the potential for ERAS-0015 to become a best-in-class therapy and its advancement into further clinical development.
At the time of this filing, ERAS was trading at $12.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $1.06 to $24.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.